Plasma-Based Multi-Omics AI for Early Lung Cancer Detection
One blood test. AI-powered precision. Results in days, not months.
BAIRI is developing an affordable, non-invasive, AI-driven blood test platform for early lung cancer detection, pulmonary nodule differentiation, tuberculosis diagnosis, and longevity medicine.
By combining plasma multi-omics, machine learning, clinical data, and hospital-ready AI deployment, BAIRI aims to transform how diseases are detected, interpreted, and managed.
From blood to biological insight.
Millions of patients are waiting for clearer answers.
Lung cancer remains one of the deadliest cancers in China and globally. CT screening can detect pulmonary nodules early, but most detected nodules are benign. Clinicians often face a difficult decision: observe for months, perform invasive biopsy, or rely on limited biomarker tools.
Traditional single-marker tests cannot capture the complex biological signals behind cancer, tuberculosis, and chronic disease progression.
There is an urgent need for an affordable, accurate, non-invasive diagnostic platform that can help physicians make faster and more confident decisions.
150M+
People at risk from lung nodules in China
95%
CT-detected pulmonary nodules are benign
<70%
Traditional single biomarker sensitivity ceiling
Days, not months
BAIRI aims to shorten diagnostic uncertainty
One blood test. Multi-omics intelligence. AI-powered clinical insight.
The BAIRI IPM Test uses a simple plasma sample to analyze multiple biological layers simultaneously.
Instead of relying on one biomarker, BAIRI's platform measures and integrates hundreds of molecular signals across proteins, metabolites, amino acids, bile acids, and structured clinical data.
Machine learning models then transform this complex biological information into clinically actionable risk scores and decision support outputs.
Blood Draw
A simple, non-invasive plasma sample collected at the point of care.
1PPdPM Analysis
Simultaneous profiling of plasma proteins, amino acids, bile acids, and related metabolic signals.
2AI Integration
Machine learning models integrate multi-omics layers with clinical data.
3Clinical Risk Score
Clear output for malignancy risk, disease differentiation, and physician review.
4BAIRI helps physicians move from uncertainty to evidence-based action.
AI makes multi-omics clinically actionable.
Cancer and chronic diseases are biologically complex. No single protein or metabolite can fully explain disease risk or progression.
BAIRI's platform captures distributed biological signals across hundreds of molecular features. Its AI engine identifies disease-associated patterns that are invisible to conventional single-marker assays.
With a growing plasma multi-omics database, BAIRI's models can continuously improve in precision, generalizability, and clinical relevance.
Plasma Multi-Omics
Proteomics, metabolomics, amino acids, bile acids, and clinical variables.
Machine Learning
Pattern recognition across high-dimensional biological data.
Clinical Integration
Risk score output designed for physician decision support.
Scalable Platform
The same technology foundation can be extended across oncology, infectious disease, chronic disease, and longevity medicine.
Validated by science. Built for real-world clinical use.
BAIRI's technology is supported by retrospective studies, prospective validation, blind testing, and published scientific research.
The platform has demonstrated strong performance in lung cancer screening, pulmonary nodule differentiation, and tuberculosis differentiation.
92%
NSCLC screening sensitivity
90%
Screening specificity
82%
Benign vs malignant pulmonary nodule differentiation accuracy
Double 90%
Tuberculosis sensitivity and specificity performance
Real-World Validation in Henan, China
In 2025, BAIRI completed a prospective cohort study across Zhengzhou and Nanyang, Henan Province, demonstrating strong real-world performance across multiple patient groups.
91.7%
accuracy
TB Group
100%
accuracy
Healthy Group
93.5%
accuracy
Non-TB Pulmonary Disease Group
BAIRI continues to expand its clinical evidence base through multi-center validation, larger datasets, and regulatory preparation.
Three product lines. One AI-powered multi-omics platform.
Lung Nodule Differentiation Test
A non-invasive blood-based test designed to help differentiate benign and malignant pulmonary nodules.
Use case
- CT tie-breaker for indeterminate nodules
- Early lung cancer risk assessment
- Physician decision support
- Large-scale population screening support
Helping doctors decide faster, with fewer invasive procedures.
Tuberculosis Diagnostic Test
A plasma multi-omics AI test designed to distinguish active tuberculosis from healthy individuals and other pulmonary diseases.
Use case
- Active TB differentiation
- Non-TB pulmonary disease differentiation
- High-burden region screening support
- Clinical triage and decision support
A new blood-based approach to infectious disease differentiation.
Longevity Medicine & Wellness Tests
A revenue-ready product line supporting longevity medicine, metabolic health, anti-aging intervention, NAD+ programs, sleep management, and precision wellness.
Use case
- Biological age assessment
- NAD+ detection and enhancement
- Metabolic anti-aging panels
- Sleep and recovery optimization
- Preventive health programs
Turning biological data into personalized longevity strategies.
BAIRI is not building only one test.
BAIRI is building a scalable AI multi-omics platform that can expand across oncology, infectious disease, chronic disease, longevity medicine, and future precision health applications.
Transforming Multi-Omics Data into Digital Biology
From Diagnosis to Understanding. From Understanding to Prediction. From Prediction to Precision Health.
BAIRI-X Lab is BAIRI's advanced research and innovation platform dedicated to next-generation AI-powered biology.
While BAIRI's core diagnostic platform combines plasma multi-omics and artificial intelligence to enable early detection and disease differentiation, BAIRI-X Lab extends this capability beyond diagnosis.
By integrating multi-omics interpretation, virtual cell modeling, biological pathway inference, digital twin technologies, and AI biological reasoning, BAIRI-X Lab aims to transform biological signals into mechanistic understanding, predictive insights, and future precision interventions.
BAIRI-X Lab is the bridge between AI Diagnostics and Digital Biology.
Explainable AI Diagnostics
Beyond risk scores.
Traditional AI diagnostic systems often provide a prediction without explaining the biological reasoning behind it.
BAIRI-X Lab aims to make AI diagnostics more interpretable by linking risk scores to underlying molecular pathways, immune responses, inflammatory signals, metabolic changes, and cellular states.
Potential outputs may include
- Immune activity profiling
- Inflammatory pathway analysis
- Metabolic network interpretation
- Cellular stress indicators
- Aging and regeneration signals
Before
- Risk Score: High
After
- Risk Score: High
- Inflammation ↑
- Metabolic Reprogramming ↑
- Immune Suppression ↑
- Cellular Stress ↑
Virtual Cell Engine
Digital representation of cellular states.
The Virtual Cell Engine is a computational framework designed to model how cells change during disease progression, biological stress, treatment response, and aging.
Using multi-omics data and pathway-level inference, virtual cells can help simulate cellular activation states, immune responses, metabolic adaptations, disease-associated biological changes, and cell-to-cell communication patterns.
This creates a foundation for deeper biological understanding behind diagnostic outputs.
Virtual cells can help simulate
- Cellular activation states
- Immune responses
- Metabolic adaptations
- Disease-associated biological changes
- Cell-to-cell communication patterns
Digital Lung Twin
Toward predictive modeling of lung disease progression.
BAIRI-X Lab is exploring the development of a Digital Lung Twin platform.
By integrating plasma multi-omics, CT imaging, pathology data, and longitudinal clinical records, the platform may help create a digital representation of lung disease progression.
Future capabilities may include
- Malignancy progression prediction
- Pulmonary nodule risk evolution
- Immune microenvironment modeling
- Disease trajectory forecasting
- Personalized follow-up strategy support
Today, clinicians ask
- Is this nodule malignant?
Tomorrow, Digital Lung Twin may help answer
- How likely is this nodule to progress?
- How fast may the disease evolve?
- What biological mechanisms are driving the risk?
- What monitoring strategy may be most appropriate?
Longevity Intelligence Engine
Precision longevity through biological understanding.
BAIRI-X Lab supports BAIRI's longevity medicine product line by transforming multi-omics data into personalized biological insight.
Through AI-powered biological interpretation, the platform may generate health intelligence indicators that support personalized longevity programs, preventive health strategies, and precision wellness interventions.
Health intelligence indicators may include
- Biological Age Assessment
- Immune Fitness Index
- Inflammaging Score
- Metabolic Resilience Indicators
- Cellular Regeneration Insights
- Sleep and Recovery Biology
- NAD+ and Energy Metabolism Signals
Connected longevity products
- NAD+ detection and enhancement
- Sleep management programs
- Food-drug homology wellness solutions
- Metabolic anti-aging panels
- Preventive health monitoring
Future Therapeutics Research
Exploring the next frontier of precision medicine.
BAIRI remains focused on diagnostics, clinical applications, and longevity medicine today.
At the same time, BAIRI-X Lab provides a research foundation for future applications in AI-driven biology and therapeutic discovery.
Future research directions may include
- Disease mechanism discovery
- Therapeutic target identification
- Drug repositioning research
- Precision intervention strategy design
- Traditional Chinese Medicine modernization
- AI-assisted biological pathway simulation
AI inference at the point of care.
BAIRI is developing a dedicated hospital-ready AI appliance designed for secure clinical deployment.
Instead of relying on external cloud processing, the appliance enables local AI inference within the hospital environment, supporting data security, clinical workflow integration, and faster report generation.
Direct Instrument Integration
Captures data from laboratory instruments and mass spectrometry workflows.
On-Device AI Inference
Runs the BAIRI algorithm locally without routine cloud dependency.
Data Secure by Design
Patient data remains within the hospital environment.
LIS/HIS Integration
Generates structured reports for physician review and hospital system integration.
The BAIRI AI Appliance is designed to support clinical deployment, hospital data sovereignty, and future regulatory pathways.
Patented. Published. Proprietary. Scalable.
BAIRI's competitive advantage is built on four layers: proprietary PPdPM methodology, a growing plasma multi-omics database, AI model integration and clinical validation, and hospital-ready deployment architecture.
Intellectual Property
Chinese invention patents protecting core PPdPM methodology, AI integration, and diagnostic applications.
Plasma Multi-Omics Database
3,000+ lung nodule samples today, expanding to 10,000+. Tuberculosis database exceeds 4,000 samples with larger multi-center validation planned.
Scientific Publications
Supported by peer-reviewed research in respiratory medicine, biomarker research, bioinformatics, and proteomics.
Clinical Deployment
Designed for real-world hospital use through local AI inference and LIS/HIS integration.
BAIRI-X Lab
Extends BAIRI's diagnostic platform into Digital Biology, Virtual Cell Modeling, Digital Lung Twin, and Longevity Intelligence.
Serving China. Expanding globally.
Mainland China
China has a large and growing population of patients with pulmonary nodules. BAIRI's lung nodule differentiation test is designed to address a major unmet need: affordable, accurate, non-invasive decision support for CT-detected nodules.
Hong Kong
Hong Kong provides a premium healthcare market and an early launch opportunity for private diagnostics, real-world evidence generation, and cross-border clinical collaboration.
Global Market
The global demand for early cancer detection, multi-omics diagnostics, and AI-powered clinical decision support is growing rapidly. BAIRI's platform architecture is designed for international expansion across oncology, infectious disease, chronic disease, and longevity medicine.
Clear Path to NMPA Class III Approval
BAIRI is preparing for a structured regulatory pathway in China, including multi-center prospective validation, technical documentation, and device approval preparation.
- 01
Clinical Validation
- 02
Multi-Center Trial
- 03
NMPA Innovation Designation
- 04
Technical Review
- 05
Device Approval
- 06
Hospital Deployment
A multidisciplinary team built for AI biotech commercialization.
BAIRI brings together expertise in biotech research, plasma multi-omics, artificial intelligence, clinical deployment, regulatory affairs, hospital partnerships, and international commercialization.
Julian So
Chairman & Acting CEO
Legally qualified in Singapore, Hong Kong, and the UK. Former investment banker at UBS, RBS, and Morgan Stanley. Experienced public company director and technology company executive.
Prof. Shulin Zhang
Chief Scientific Officer
Inventor of the PPdPM platform. Expert in molecular genetics, plasma multi-omics, and translational biomedical research.
Darry Huang
Chief Information Officer
Leads BAIRI's AI, machine learning, clinical deployment, software architecture, and LIS/HIS integration. Responsible for transforming BAIRI's diagnostic technology into a hospital-ready AI platform.
Dr. Zizhuo Wu
Founding Director, BAIRI-X Lab
Leads BAIRI-X Lab's Digital Biology research — virtual cell modeling, AI biological reasoning, disease mechanism inference, and computational biomedical discovery.
Sun Zhanqiang
Dean / Chief Regulatory & Commercialization Officer, China
Responsible for China regulatory strategy, commercial partnerships, clinical deployment, and diagnostic service development.
Adrian Watson
COO, Hong Kong
Oversees Hong Kong operations, regulatory compliance, private clinic partnerships, and regional business development.
Li Ning
COO, China
Leads China subsidiary daily operations, NMPA coordination, hospital partnerships, and diagnostic service execution.
Feng Jian
Business Development & Sales
Responsible for diagnostic distribution, sales partnerships, institutional outreach, and commercial channel development.
Gao Cheng
Partnership Development
Drives strategic alliances with hospitals, diagnostic partners, institutional networks, and regional healthcare systems.
Wang Liang
Senior R&D Researcher
Leads multi-omics research, assay development, and scientific validation support.
We welcome clinical collaborators, healthcare partners, diagnostic distributors, and strategic investors.
BAIRI is building an AI-powered multi-omics platform for early detection, disease differentiation, longevity medicine, and next-generation digital biology.
We welcome collaboration with
- Hospitals
- Clinical research institutions
- Diagnostic laboratories
- Healthcare systems
- Wellness and longevity clinics
- Biotech companies
- Strategic investors
- Government and regional health partners
One blood test. AI-powered precision. Results in days, not months.
From diagnosis to Digital Biology.